Cytogenetic subgroup analysis of the advance trial: A randomized multi-center study of carfilzomib, lenalidomide and dexamethasone (KRd) with or without daratumumab (D) in patients with newly diagnosed multiple myeloma (NDMM)
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-5763
Abstract: Introduction: Cytogenetic abnormalities such as del(17p), t(4;14), and gain(1q), among others and particularly when co-occurring, are associated with high-risk disease and inferior outcomes in newly diagnosed multiple myeloma (NDMM). The randomized phase 2 ADVANCE study… read more here.
Keywords: subgroup; mrd negativity; krd without; krd ... See more keywords